AstraZeneca and Bristol Myers Squibb Deny $400 Billion Merger Talks

Pharmaceutical companies AstraZeneca and Bristol Myers Squibb have denied that they are currently engaged in merger discussions or have ever held such talks. The denials follow several days of reports suggesting the companies had held preliminary conversations to create a combined entity valued at approximately $400 billion with annual revenues of $107 billion.

The reports triggered a sharp market reaction on August 3, 2026, with AstraZeneca shares plunging as much as 9 percent and erasing approximately $22 billion in market value. Bristol Myers Squibb shares initially rose up to 3.8 percent before later declining. Analysts from Jefferies, HSBC, and Citi expressed skepticism regarding the strategic logic of the deal, noting that Bristol Myers Squibb faces looming patent expirations for key drugs Eliquis and Opdivo, while AstraZeneca has maintained strong independent growth.

Industry experts warned that any such transaction would have faced significant antitrust scrutiny from the Donald Trump administration due to overlapping oncology and cardiovascular portfolios. Some analysts suggested the deal could only be viable through aggressive cost-cutting and asset aggregation. Prior to the reports, AstraZeneca CEO Pascal Soriot had stated the company did not require mergers and acquisitions to thrive, citing a robust pipeline of 16 blockbuster medicines.